UK markets open in 2 hours 25 minutes
NIKKEI 225
38,760.42 +524.35 (+1.37%) HANG SENG
18,420.38 -157.92 (-0.85%) CRUDE OIL
78.73 +0.25 (+0.32%) GOLD FUTURES
2,332.40 +1.20 (+0.05%) DOW
38,852.27 +176.59 (+0.46%) Bitcoin GBP
50,481.66 -400.08 (-0.79%)
Krystal Biotech, Inc. (4KB.F)
Frankfurt - Frankfurt Delayed price. Currency in EUR
Add to watchlist
At close: 09:24AM CEST
| Previous close | 149.20 |
| Open | 148.80 |
| Bid | 143.80 x 0 |
| Ask | 145.00 x 0 |
| Day's range | 148.80 - 148.80 |
| 52-week range | 78.50 - 167.80 |
| Volume | |
| Avg. volume | 13 |
| Market cap | 4.27B |
| Beta (5Y monthly) | 0.86 |
| PE ratio (TTM) | 413.33 |
| EPS (TTM) | 0.36 |
| Earnings date | 05 Aug 2024 - 09 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 98.43 |
GuruFocus.comKrystal Biotech Inc (KRYS) Surpasses Revenue Estimates in Q1 2024
Details on Financial Performance and Strategic Progress
ZacksKrystal Biotech, Inc. (KRYS) Q1 Earnings and Revenues Miss Estimates
Krystal Biotech (KRYS) delivered earnings and revenue surprises of -85% and 0.57%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
GlobeNewswireKrystal Biotech Announces First Quarter 2024 Financial Results and Provides Business Updates
Net product revenue of $45.3 million in 1Q and $95.9 million since AugustFirst patient dosed in inhaled KB707 study for locally advanced or metastatic tumors of the lungReceived Fast Track Designations for both inhaled and intratumoral KB707Strong balance sheet with $622.3 million in cash and investments PITTSBURGH, May 06, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today reported financial results and key business upd
© 2024 Yahoo. All rights reserved.